Skip to main content

Incyte Value Stock - Dividend - Research Selection


ISIN: US45337C1027, WKN: 896133

Market price date: 15.08.2022
Market price: 75,28 USD

Incyte Fundamental data and company key figures of the share

Annual reports in USD
Key figures 11-02-2022
Cash flow
Net operating cash flow 749.488.000
Capital Expenditures -181.006.000
Free cash flow 568.481.984
Balance sheet
Total Equity 3.770.000.000
Liabilities & Shareholders equity 4.933.350.000
Income statement
Net income 948.581.000
Eps (diluted) 4,270
Diluted shares outstanding 222.248.000
Net sales/revenue 2.986.270.000

Fundamental ratios calculated on: 15-08-2022

Key figures 15-08-2022
Cash flow
P/C 21,94
P/FC 29,43
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization16.444.129.280,00 USD
CountryUnited States
IndicesMSCI World Index,NASDAQ Comp.,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split2000-09-01,2.0000/1.0000; 1997-11-10,2.0000/1.0000

Description of the company

Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Trading The Top 10 Stocks From 40 Large Hedge Funds: Trading Update 8/7/2022

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management.

Incyte Corp. stock outperforms competitors on strong trading day

Shares of Incyte Corp. inched 0.35% higher to $72.16 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...

Incyte Corp. stock falls Thursday, underperforms market

Shares of Incyte Corp. slipped 0.87% to $71.91 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...

Incyte Corp. stock underperforms Wednesday when compared to competitors

Shares of Incyte Corp. sank 0.06% to $72.54 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...

Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares Crumbled

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations.

Incyte Corp. stock falls Tuesday, underperforms market

Shares of Incyte Corp. shed 6.23% to $72.58 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...

NEW YORK MARKET CLOSE: Stocks slide as Pelosi touches down in Taiwan

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

INCYTE CORP Management's Discussion and Analysis of Financial Condition and Resultsof Operations (form 10-Q)

The following discussion of our financial condition and results of operations asof and for the three and six months ended June 30, 2022 should be read inconjunction with the unaudited condensed... | August 2, 2022

Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2

Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.

Incyte Q2 Earnings Beat Estimates But Tightens FY22 Jakafi Sales Guidance

Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $1.01, compared to $0.8067 posted a year ago. Analysts had estimated $0.75. Sales increased 29% Y/Y to $911.39 million, beating the consensus of $815.17 million. The company reported an operating income of $254.43 million, compared to $140.84 million posted a year ago. Jakafi net product revenues increased 13% Y/Y to $597.67 million, primarily driven by volume growth. The company said that the launch of Opzelura in atopic dermatitis con